Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and if seizures are well controlled
253.0
Patients who are currently receiving enzyme inducing anticonvulsants are not eligible
253.0
Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible
74.0
TUMOR BIOPSY SEQUENCING: Patients with history of central nervous system (CNS) metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for 4 weeks will be eligible; enzyme-inducing anticonvulsants are contraindicated
700.0
TREATMENT: Patients with a history of seizures are not eligible to receive veliparib, but patients with a history of CNS metastases who have received treatment and who either have not had seizures or have been on stable doses of anti-seizure medicine and had no seizures for >= 4 weeks will be eligible for other study agents; enzyme inducing anticonvulsants are contraindicated
700.0
TREATMENT: Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial; patients who have a history of seizures are not eligible to receive veliparib, but patients who have either not had seizures or who have been on stable doses of anti-seizure medicine and had no seizures for 4 weeks will be eligible for other study agents; enzyme-inducing anticonvulsants are contraindicated
700.0
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
77.0
Patients must not currently be receiving enzyme inducing anticonvulsants
77.0
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
154.0
Patients must not have received enzyme inducing anticonvulsants for at least 14 days prior to enrollment
154.0
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
81.0
Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlled
56.0
Central nervous system function defined as:* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled* Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollment
45.0
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
65.0
Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled
146.0
Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled
51.0
Patients must not have received enzyme-inducing anticonvulsants for at least 7 days prior to enrollment
51.0
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
49.0
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
144.0